

Date: 8th March, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir / Madam,

Sub: US FDA Inspection at Alembic Pharmaceuticals Limited's Oncology (Injectable and Oral Solid) Formulation Facility at Panelav

We would like to inform that the United States Food and Drug Administration (US FDA) has conducted an inspection at our Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav from 28th February, 2024 to 8th March, 2024. The US FDA issued a Form 483 with four procedural observations.

The Company will provide comprehensive response to USFDA for the observations within the stipulated period.

The Company is committed to maintain the highest quality standards and compliance at all times.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED